Skip to main content
SpringerLink
Log in

Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients

  • Brief Report
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

Abstract

Objective

Critical illness and associated sequelae can cause severe metabolic disturbances. The effects these have on hepatic drug metabolism are poorly understood. In vivo, enzyme specific drug probes are used to measure changes in hepatic drug metabolism but they require multiple blood sampling and are time consuming. We suggest that a single measurement, 4 h after intravenous administration of midazolam is a reliable indicator of integral plasma midazolam exposure or area under the curve (AUC) in critically ill patients. We also explore the hypothesis that acute kidney injury (AKI) directly impairs hepatic metabolism of drugs in critically ill patients.

Methods

A prospective study in 20 critically ill patients who were not taking specific enzyme inhibitors or inducers or benzodiazepines. Correlation between 4 h midazolam concentration and AUC was calculated. We also assessed the difference in metabolism between the patients with normal renal function and those with AKI.

Results

Four hour midazolam concentration correlated with AUC r = 0.956 (p < 0.0001). In addition, the 4 h midazolam concentration was greater in critically ill patients with AKI than those with normal renal function p = 0.023.

Conclusion

A single-time-point determination of plasma midazolam concentration is a reliable predictor of integral plasma midazolam exposure in critically ill patients. This tool can now be used to assess the effects of critical illness on hepatic drug metabolism. Using this method, we suggest that AKI reduces the hepatic metabolism of midazolam in critically ill patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Paulussen A, Lavrijsen K, Bohets H, Hendrickx J, Verhasselt P, Luyten W, Konings F, Armstrong M (2000) Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10:415–424

    Article  PubMed  CAS  Google Scholar 

  2. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17

    Article  PubMed  CAS  Google Scholar 

  3. Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, Shen DD, Watkins PB, Wilkinson GR, Kharasch ED, Thummel KE (2001) In vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11:781–791

    Article  PubMed  CAS  Google Scholar 

  4. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643–1653

    Article  PubMed  CAS  Google Scholar 

  5. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595–606

    Article  PubMed  CAS  Google Scholar 

  6. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM et al (1994) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271:549–556

    PubMed  CAS  Google Scholar 

  7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470

    PubMed  CAS  Google Scholar 

  8. Bellomo R, Kellum J, Ronco C (2001) Acute renal failure: time for consensus. Intensive Care Med 27:1685–1688

    Article  PubMed  CAS  Google Scholar 

  9. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 68:82–91

    Article  PubMed  CAS  Google Scholar 

  10. Zimmerman CL, Slattery JT (1983) Maintenance-dose prediction based on a single determination of concentration: general applicability to two-compartment drugs with reference to lithium. J Pharm Sci 72:1262–1266

    Article  PubMed  CAS  Google Scholar 

  11. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 66:288–294

    Article  PubMed  CAS  Google Scholar 

  12. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162–172

    Article  PubMed  CAS  Google Scholar 

  13. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391

    Article  PubMed  CAS  Google Scholar 

  14. Guevin C, Michaud J, Naud J, Leblond FA, Pichette V (2002) Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 137:1039–1046

    Article  PubMed  CAS  Google Scholar 

  15. Michaud J, Dube P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V (2005) Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 144:1067–1077

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. General Intensive Care, St George’s University of London, St Georges Hospital Blackshaw Road, London, SW17 0QT, UK

    Christopher John Kirwan, R. Michael Grounds & Barbara J. Philips

  2. Analytical Unit, St George’s University of London, London, UK

    Terry Lee & David W. Holt

  3. Renal and Transplant Medicine, St George’s University of London, London, UK

    Iain A. M. MacPhee

Authors
  1. Christopher John Kirwan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terry Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David W. Holt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Michael Grounds
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Iain A. M. MacPhee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Barbara J. Philips
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher John Kirwan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirwan, C.J., Lee, T., Holt, D.W. et al. Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Med 35, 1271–1275 (2009). https://doi.org/10.1007/s00134-009-1430-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-009-1430-7

Keywords

Search

Navigation